Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 9/20 | 0.65 |
| ▸ | MTTP | P55157 | 7/20 | 0.51 |
| ▸ | APOB | P04114 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742603 | 0.92 | NPY2R (0.68) | NPY2RMTTPAPOBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2588198 | 0.91 | NPY2R (0.67) | NPY2RMTTPAPOBKDM4EALDH1A1 | |
| SCHEMBL12174540 | 0.90 | NPY2R (0.66) | NPY2RMTTPKDM4EALDH1A1LMNA | |
| SCHEMBL2582758 | 0.89 | NPY2R (0.83) | NPY2RMTTPAPOBGAA | |
| SCHEMBL6708421 | 0.88 | NPY2R (0.62) | NPY2RMTTPAPOBKDM4EALDH1A1 | |
| SCHEMBL12174502 | 0.88 | NPY2R (0.70) | NPY2RMTTPKDM4EALDH1A1LMNA | |
| SCHEMBL12174389 | 0.87 | NPY2R (0.64) | NPY2RMTTP | |
| SCHEMBL2579661 | 0.86 | NPY2R (0.61) | NPY2RMTTP | |
| SCHEMBL13522038 | 0.86 | NPY2R (0.61) | NPY2RMTTP | |
| SCHEMBL2586192 | 0.86 | NPY2R (0.67) | NPY2RMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | claimed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | claimed |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | NPY2R 983/4885MTTP 6/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.